Merck & Co., Inc. MRK

148.78 0.80 0.54% as of 25 Sep
Market cap
$365.4B
P/E
119×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years

Merck & Co., Inc. (MRK) EV/Sales

As of 25 September 2026, Merck & Co., Inc. (MRK) trades at a EV/Sales of 6.2×. Over the past ten years it has ranged from 3.3× (May 2025) to 6.5× (August 2026); the current reading is higher than 100% of that period. That is above the Drug Manufacturers General industry median of 4.0× and above the Healthcare sector median of 3.6×.

EV/Sales, daily

Annual

Period EV/Sales Change
FY2025 4.5× 6.99%
FY2024 4.2× (18.62%)
FY2023 5.2× 4.23%
FY2022 5.0× 12.69%
FY2021 4.4× (14.07%)
FY2020 5.2× (13.84%)
FY2019 6.0× 23.76%
FY2018 4.9× 22.17%
FY2017 4.0× (6.30%)
FY2016 4.2× 9.89%

Quarterly

Period EV/Sales Change
Jun 2026 5.4× 5.51%
Mar 2026 5.1× 13.16%
Dec 2025 4.5× 26.33%
Sep 2025 3.6× 2.19%
42 more quarters

Against its own ten years

Low 3.3× High 6.5×
Ten-year median 4.6×
Current reading's percentile 100

EV/Sales against peers

Company EV/Sales
PFE Pfizer Inc. compare 3.4×
NVO Novo Nordisk A/S compare 3.6×
AZN AstraZeneca PLC compare 4.6×
NVS Novartis AG compare 5.6×
MRK Merck & Co., Inc. 6.2×
JNJ Johnson & Johnson compare 6.8×
GILD Gilead Sciences, Inc. compare 6.9×
AMGN Amgen Inc. compare 7.0×
ABBV AbbVie Inc. compare 8.3×
Drug Manufacturers General industry median 4.0×
Healthcare sector median 3.6×
Market median 2.2×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on MRK